Frank Dombrowski, Matthias Evert – 26 February 2007 – The microarchitecture of the liver is still not completely understood although various concepts of structural liver organization have been proposed. Among them, Rappaport's liver acinus stands out as one of the most accepted models. The correctness of this model, however, has also been doubted, and its applicability is hampered by the fact that the outlines of the liver acinus are disguised and nobody was ever able to give visual evidence by “unmasking” a simple liver acinus from the surrounding liver tissue.

Gerald Y.

Zobair Younossi, Jillian Kallman, John Kincaid – 26 February 2007 – Infection with HCV leads to an array of symptoms that compromise health‐related quality of life (HRQL). Chronic hepatitis C is treated primarily with pegylated interferon (peg‐IFN) and an inosine 5′ monophosphate dehydrogenase inhibitor, ribavirin (RBV), with the goal of achieving a sustained virologic response (SVR). SVR reduces the rate of hepatic fibrosis and other disease‐related complications and, in turn, increases HRQL.

Chun‐Jung Chang, Yi‐Hsiang Chen, Kai‐Wen Huang, Hao‐Wei Cheng, Suit‐Fong Chan, Kuo‐Feng Tai, Lih‐Hwa Hwang – 26 February 2007 – Immunotherapy is often effective only for small tumor burdens and, in many cases, is restricted to subcutaneous tumors. Here, we investigated the antitumor effects of combination therapy with GM‐CSF and IL‐12 on orthotopic liver tumors with intermediate or large tumor volumes, or on chemically‐induced multifocal liver tumors in animals.

Sabine Oertelt, Roman Rieger, Carlo Selmi, Pietro Invernizzi, Aftab A. Ansari, Ross L. Coppel, Mauro Podda, Patrick S.C. Leung, M. Eric Gershwin – 26 February 2007 – The antimitochondrial response in primary biliary cirrhosis (PBC) is the most highly directed and specific self‐reacting antibody in human immunopathology. Originally, antimitochondrial antibodies (AMAs) were detected by indirect immunofluorescence (IIF) and found in approximately 90% of well‐documented patients with PBC.

Janet King, Kris V. Kowdley – 26 February 2007

Jasmohan Singh Bajaj, Ashkan Etemadian, Muhammad Hafeezullah, Kia Saeian – 26 February 2007

Benjamin L. Shneider, Eve A. Roberts, Regino P. González‐Peralta – 26 February 2007

Christine S. Rollier, Glaucia Paranhos‐Baccala, Ernst J. Verschoor, Babs E. Verstrepen, Joost A. R. Drexhage, Zahra Fagrouch, Jean‐Luc Berland, Florence Komurian‐Pradel, Blandine Duverger, Nourredine Himoudi, Caroline Staib, Marcus Meyr, Mike Whelan, Joseph A. Whelan, Victoria A. Adams, Esther Larrea, José I. Riezu, Juan José Lasarte, Birke Bartosch, Francois‐L. Cosset, Willy J. M. Spaan, Helmut M. Diepolder, Gerd R. Pape, Gerd Sutter, Genevieve Inchauspe, Jonathan L.

Ronald Koschny, Tom M. Ganten, Jaromir Sykora, Tobias L. Haas, Martin R. Sprick, Armin Kolb, Wolfgang Stremmel, Henning Walczak – 26 February 2007 – Tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) represents a novel promising anticancer biotherapeutic. However, TRAIL‐resistant tumor cells require combinatorial regimens to sensitize tumor but not normal cells for TRAIL‐induced apoptosis.